% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • desert_dweller93 desert_dweller93 Jan 22, 2013 10:28 PM Flag

    ASCO GI abstract for ASG-5ME

    Abstract is out for the phase 1 study for pancreatic cancer.

    A phase I study of ASG-5ME, a novel antibody-drug conjugate, in pancreatic ductal adenocarcinoma

    .....Thus, 1.2 mg/kg was identified as the MTD and expanded (N=18). The most common AEs observed at the MTD were fatigue (50%), vomiting (44%), decreased appetite (39%), nausea (33%), and abdominal pain (33%); Grade 3 or 4 toxicities at the MTD included fatigue (28%), abdominal pain (22%), vomiting (17%), and neutropenia (17%). Antitumor activity was observed: 1 pt achieved an unconfirmed PR and 12 pts achieved SD. Five patients (14%) had reductions in CA19-9. Serum ASG-5ME exposures were approximately dose proportional. Of 23 pts with archived biopsies available for IHC analysis, 100% expressed SLC44A4 and 15 pts (65%) had high expression. Conclusions: ASG-5ME treatment was generally well tolerated in metastatic PDA pts, with preliminary evidence of antitumor activity. Further study of ASG-5ME in SLC44A4-expressing malignancies is warranted. Clinical trial information: NCT01166490.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
43.99-0.41(-0.92%)Jul 22 4:00 PMEDT